Zepbound reduced heart failure risk in a late-stage study
Gokhan says weight loss is the best drug in obesity and new GLP-1 drugs can aid it, sharing a CNBC report that Eli Lilly's Zepbound cut heart failure risk in a late-stage study, adding to evidence of benefits beyond weight and glucose control.
